Real life approach and treatment of chronic urticaria in Argentina: A National Survey

TORRE, ANA C.; BOLLEA GARLATTI, MARIA L.; MARCIANO, SEBASTIÁN; POSADAS-MARTINEZ, MARÍA L.; PARISI, CLAUDIO A. S.; MAZZUOCCOLO, LUIS D.

DERMATOLOGIC THERAPY

WILEY-BLACKWELL PUBLISHING, INC

Año: 2019

1396-0296

Dermatol Ther. 2019 Sep 12:e13086. doi: 10.1111/dth.13086. [Epub ahead of print]Real-life approach and treatment of chronic urticaria in Argentina: A National Survey.Torre AC1,2, Bollea Garlatti ML1, Marciano S3, Posadas-Martinez ML3, Parisi CAS2,4, Mazzuoccolo LD1.Author information1Department of Dermatology, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.2UCARE center, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.3Department of Research, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.4Department of Internal Medicine, Allergy Section, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.AbstractThe management of chronic urticaria (CU) has been controversial. Recently updated international guidelines propose evidence-based diagnosis and treatment. Nevertheless, dermatologists have heterogeneous approaches to managing CU. To estimate the percentage of dermatologists who have an optimal approach to CU according to the international guidelines, and to explore the variables associated with optimal management a cross-sectional study using a 17-question survey was delivered by email to dermatologists from Argentina. Optimal first, second, and third line treatment were considered when dermatologists chose a nonsedative antihistamine; increased the dosage of nonsedative antihistamines, and added omalizumab, respectively. Logistic regression was used to identify variables associated with optimal management. A total of 165 questionnaires were available for analysis. An optimal first, second, and third-line treatment approach was identified in 50%, 35%, and 15% of the dermatologists, respectively. The dermatologists´ age being above 55 years old (OR: 0.12, 95% CI: 0.01-0.99, p .005) and having more than 5 years of expertise (OR: 0.4, 95% CI: 0.19-0.81, p .001) were significantly associated with a suboptimal approach in second-line treatment. We could not find variables associated with an optimal first or third-line treatment. The real-life management of CU in Argentina is partly suboptimal according to the international guidelines.© 2019 Wiley Periodicals, Inc.KEYWORDS:guidelines; knowledge; survey; therapeutics; urticaria